Corcept Therapeutics Incorporated - Common Stock — Cash Flow (NASDAQ:CORT) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities 151.97 M167.89 M120.32 M127.04 M198.07 M142 M 120.45 M Cash from investing activities -119.26 M136.13 M-114.33 M90.91 M-177.6 M69.76 M 77.47 M Cash from financing activities 12.21 M-302.59 M-17.28 M-148.72 M-28.35 M-220.37 M -179.8 M Free cash flow 151.97 M167.89 M120.32 M127.04 M198.07 M142 M 120.45 M

News

Corcept Therapeutics: Recent Relacorilant Rejection Aside, A Good News Story

Corcept Resubmits NDA for Relacorilant in Cushing's Syndrome

CORT Stock Rises 42% in a Month: Here's What You Should Know

Why Is United Therapeutics (UTHR) Down 3.8% Since Last Earnings Report?

CORT to Resubmit NDA for Relacorilant in Cushing's Syndrome, Stock Up

Wall Street Analysts Believe Corcept (CORT) Could Rally 43.32%: Here's is How to Trade

Will Korlym Continue to Aid CORT's Growth in 2026 After a Strong Q1?

S&P 500 and Nasdaq 100 Post New Record Highs on Chip Stock Strength

Chip Stock Strength Lifts the Broader Market

Stocks Pressured by Signs of Resurgent Inflation

Corcept: 'Strong Buy' On Lifyorli FDA Approval And ALS Phase 3 Advancement (NASDAQ:CORT)

CORT Q1 Earnings Match Estimates, Revenues Miss, 2026 Outlook Raised